Hikma Pharmaceuticals Plc Director/PDMR Shareholding (8766Z)
15 January 2020 - 8:44PM
UK Regulatory
TIDMHIK
RNS Number : 8766Z
Hikma Pharmaceuticals Plc
15 January 2020
1.1 Annex DTR3
Notification of Transactions of Directors/Persons Discharging
Managerial Responsibility and Connected Persons
All relevant boxes should be completed in block capital
letters
State whether the notification
relates to (i) a transaction
notified in accordance with
DTR 3.1.2 R, (ii) a disclosure
made in accordance with
LR 9.8.6R(1) or (iii) a
disclosure made in accordance
with section 793 of the
Name of the Issuer: Companies Act (2006):
1. Hikma Pharmaceuticals PLC 2. DTR 3.1.2 R
State whether notification
relates to a person connected
with a person discharging
Name of person discharging managerial responsibilities/
managerial responsibilities/director: director named in 3 and
Said Darwazah, Mazen Darwazah identify the connected person:
3. and Ali Al-Husry 4. Yes: Darhold Limited
--------------------------------------- ---- -----------------------------------
Indicate whether the notification
is in respect of a holding
of the person referred to Description of shares (including
in 3 or 4 above or in respect class), debentures or derivatives
of a non-beneficial interest: or financial instruments
Beneficial interest in Darhold relating to shares:
5. Limited 6. Ordinary Shares
--------------------------------------- ---- -----------------------------------
Name of registered shareholders(s)
and, if more than one, the State the nature of the
number of shares held by transaction:
each of them: Pledge of 2,345,000 Ordinary
7. EFG Bank 8. Shares in support of a loan
--------------------------------------- ---- -----------------------------------
Percentage of issued class
acquired (treasury shares
Number of shares, debentures of that class should not
or financial instruments be taken into account when
relating to shares acquired: calculating percentage):
9. None 10. N/A
--------------------------------------- ---- -----------------------------------
Percentage of issued class
disposed (treasury shares
Number of shares, debentures of that class should not
or financial instruments be taken into account when
relating to shares disposed: calculating percentage):
11. None 12. N/A
--------------------------------------- ---- -----------------------------------
Price per share or value
of transaction: Date and place of transaction:
13. N/A 14. Amman, 15 January 2020
--------------------------------------- ---- -----------------------------------
Total holding following
notification and total percentage
holding following notification
(any treasury shares should
not be taken into account Date issuer informed of
when calculating percentage): transaction:
15. 60,000,000 - 24.76 per cent. 16. 15 January 2020
--------------------------------------- ---- -----------------------------------
If a person discharging managerial responsibilities has been
granted options by the issuer complete the following boxes
------------------------------------------------------------------------------
Period during which or date
17. Date of grant 18. on which exercisable
--------------------------------- ---- -------------------------------
Total amount paid (if Description of shares or
any) for grant of the debentures involved (class
19. option 20. and number)
--------------------------------- ---- -------------------------------
Exercise price (if fixed
at time of grant) or indication Total number of shares or
that price is to be fixed debentures over which options
21. at the time of exercise 22. held following notification
--------------------------------- ---- -------------------------------
Name of contact and telephone
23. Any additional information 24. number for queries
--------------------------------- ---- -------------------------------
Name of authorised official or issuer responsible for making
notification
Peter Speirs, Company Secretary, Hikma Pharmaceuticals PLC
Date of notification: 15 January 2020
Notes:
This form is intended for use by an issuer to make a RIS
notification required by DTR 3.1.4
(1) An issuer making a notification in respect of a transaction
relating to the shares or debentures of the issuer should complete
boxes 1 to 16, 23 and 24.
(2) An issuer making a notification in respect of a derivative
relating the shares of the issuer should complete boxes 1 to 4, 6,
8, 13, 14, 16, 23 and 24.
(3) An issuer making a notification in respect of options
granted to a director/person discharging managerial
responsibilities should complete boxes 1 to 3 and 17 to 24.
(4) An issuer making a notification in respect of a financial
instrument relating to the shares of the issuer (other than a
debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16,
23 and 24.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHGCGDBGSBDGGU
(END) Dow Jones Newswires
January 15, 2020 04:44 ET (09:44 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024